1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
MacKenzie Realty Capital reported fiscal 2026 results for the year ended June 30, 2026, with net revenues down 9% and net loss down 41%. The same day, its Board temporarily suspended the Preferred Share Repurchase Program so it can react to strategic alternatives that its financial advisor, Maxim Group LLC, may bring. The Board says the company's issuance of common stock in exchange for preferred shares added selling pressure on the common stock, and it expects to reassess the program in due course.
Net revenues were $20.01 million for fiscal 2026, down 9% from $22.06 million in fiscal 2025.
Net loss was $14.13 million, down 41% from $23.97 million; net operating loss was $15.61 million, down 33% from $23.46 million.
The Preferred Share Repurchase Program is temporarily suspended; the Board expects to reassess it in due course.
The company says there can be no assurance that it will enter into any strategic transaction.
KLX Energy Services completed its subscription rights offering on September 29, 2026, selling 24,975,001 shares at $1.49 each for $37.2 million in gross proceeds. Backstop holders of its 2030 Notes exchanged them for 59,273,445 shares, cutting outstanding principal by $94.0 million, and the company expects 105,677,168 shares outstanding afterward, so existing shareholders will be diluted. The 2030 Notes indenture was also amended to loosen leverage tests, which gives the company more covenant flexibility.
Rights offering: 24,975,001 shares sold at $1.49 per share for $37.2 million gross; $31.0 million for general corporate purposes and $6.2 million to redeem 2030 Notes at par on October 10, 2026
Backstop exchange: 59,273,445 shares issued to Backstop Parties; 2030 Notes principal reduced by $94.0 million; 105,677,168 shares expected outstanding
Indenture amended: total net leverage incurrence test relaxed from 2.50:1.00 to 3.00:1.00; maintenance covenant step-down reset to 4.50:1.00 starting with the quarter ending September 30, 2026
Beasley Broadcast Group closed a registered direct offering and a concurrent private placement on September 30, 2026, selling 200,000 Class A shares at $14.00 each, pre-funded warrants for up to 157,000 shares, and common warrants for 357,000 shares exercisable at $15.00. The company expects net proceeds of about $4.3 million, which it plans to use with proceeds from asset sales to reduce revolver borrowings and redeem part of its 11.000% notes due 2028, but the sales add shares and warrants that could dilute existing shareholders.
200,000 Class A shares sold at $14.00 each to a single institutional investor, plus pre-funded warrants for up to 157,000 shares
Common warrants for 357,000 shares at a $15.00 exercise price, initially exercisable six months after issuance
Net proceeds of about $4.3 million after a 6.0% placement agent fee; about $2.2 million to reduce revolver borrowings and about $11.4 million to redeem 11.000% notes due 2028
Company agreed not to issue more equity for 60 days and not to enter variable rate transactions for 180 days after the September 30, 2026 closing
TTM Technologies completed its acquisition of Epiq Solutions on September 30, 2026, paying approximately $1.1 billion in cash, subject to customary adjustments. The purchase was funded with new term loans under a Third Amended and Restated Credit Agreement and proceeds from the company's 6.750% senior notes due 2034. The company expects the deal to be immediately accretive to adjusted EBITDA, moderately dilutive to non-GAAP diluted EPS in 2027, and accretive to non-GAAP diluted EPS in 2028.
Purchase price of approximately $1.1 billion in cash, paid to the seller on September 30, 2026, subject to working capital and other adjustments
New incremental facilities of $300 million term loan A and $800 million seven-year term loan B, with JPMorgan Chase Bank, N.A. as administrative agent
Company expects immediate accretion to adjusted EBITDA, moderate dilution to non-GAAP diluted EPS in 2027, and accretion in 2028
On September 29, 2026, Inogen agreed to sell substantially all assets of its U.S. oxygen rental business to Rotech Healthcare for an estimated up to $24.8 million, subject to post-closing reconciliation and payable in six installments. The filing also discloses a supply agreement with Rotech and a conditional increase in the share repurchase authorization to $45.0 million, effective only if the sale closes, which matters to shareholders because it removes a business with declining revenue while expanding capital return.
Purchase price is estimated at up to approximately $24.8 million, payable in six installments and subject to post-closing reconciliation.
The rental business generated $24.3 million of revenue in the first half of 2026, down 9.8% year over year.
Share repurchase authorization would rise from $30.0 million to $45.0 million and expire June 30, 2028 instead of December 31, 2027, but only upon closing.
The transaction is expected to close in the fourth quarter of 2026, and the rental business will be reported as discontinued operations starting with third-quarter 2026 results.
Progress Software reported fiscal third-quarter 2026 revenue of $246 million, down 2% year-over-year, while GAAP diluted earnings per share rose 25% to $0.55. The company raised its fiscal 2026 revenue and non-GAAP EPS guidance but cut its GAAP EPS guidance and expects a GAAP loss per share in the fourth quarter, and it closed its acquisition of Domo's AI and data platform business.
Q3 revenue was $246 million, down 2% year-over-year; ARR was $873 million, up 1% on a constant currency basis.
Fiscal 2026 revenue guidance was raised to $1,044 million-$1,052 million from $990 million-$1,002 million; GAAP diluted EPS guidance was cut to $1.18-$1.28 from $1.60-$1.74.
Fourth-quarter 2026 GAAP diluted loss per share is guided at $(0.41) to $(0.32); non-GAAP diluted EPS is guided at $1.24 to $1.33.
Q3 non-GAAP diluted EPS was $1.69, up 13% from $1.50; cash and cash equivalents were $113.7 million at quarter end.
All In FutureTech Alliance disclosed that counsel for stockholder Primo Vital Limited sent letters in May and September 2026 claiming that its prior beneficial ownership disclosures about director Jingsheng (Jason) Lu were inaccurate. The company says it takes no position on the dispute over 11,986,523 shares it reported as roughly 31.3% of its common stock, and that this report does not resolve who controlled those shares.
Primo Letters dated May 22, 2026 and September 2, 2026 claim Mr. Lu was removed as Primo's director on May 19, 2026 and lost authority on March 3, 2026, when Ourgame was placed into liquidation in the Cayman Islands.
The company's Form 10-K and Special Meeting Proxy Statement reported Primo as record holder of 11,986,523 shares, about 31.3% of common stock, with shared voting power held by Mr. Lu.
The company relied on a December 11, 2024 joint Schedule 13D/A and says it will evaluate further information and its disclosure obligations.
Moving iMage Technologies reported fiscal 2026 net sales of $17.3 million, down 4.6% from the prior year, while its net loss narrowed to $297,000 from $948,000 on higher gross margin. Fourth-quarter sales fell to $4.55 million from $5.88 million and the quarterly net loss widened, and the company expects first-quarter fiscal 2027 revenue of about $4.5 million.
FY2026 net sales were $17.3 million, down 4.6% from $18.1 million in FY2025.
Gross profit rose 10% to $5.0 million, and net loss per share improved to $(0.03) from $(0.10).
Q4 2026 net sales were $4.55 million versus $5.88 million in Q4 2025, and the Q4 net loss was $296,000 versus $156,000.
The company ended FY2026 with $3.2 million in cash and zero debt, after $2.5 million of net cash used in operating activities.
Conagra Brands reported first-quarter fiscal 2027 results for the period ended August 30, 2026, with net sales down 1.4% to $2.6 billion while diluted EPS rose 5.9% to $0.36 and adjusted EPS rose 5.1% to $0.41. The company reaffirmed its full-year fiscal 2027 guidance, including adjusted EPS of $1.40 to $1.50, so shareholders see weaker sales offset by higher profit and no change to the outlook.
Net sales fell 1.4% to $2.6 billion; organic net sales decreased 1.1%, driven by a 2.1% volume decrease.
Diluted EPS was $0.36, up 5.9%; adjusted EPS was $0.41, up 5.1%, helped by lower adjusted SG&A and higher equity method earnings.
Fiscal 2027 guidance reaffirmed: adjusted EPS of $1.40 to $1.50 and adjusted operating margin of 10.0% to 10.5%.
Free cash flow was ($128) million, a decrease of $102 million; net debt was $7.4 billion, with a 3.99x net leverage ratio.
Connect Biopharma reported preliminary topline results from its Phase 2 Seabreeze STAT COPD study of rademikibart as an add-on treatment for acute COPD exacerbations, with 159 participants randomized 1:1. The primary endpoint, treatment failure through Week 4, was reduced 81% versus placebo (p=0.0122), but the key secondary FEV1 result at Week 4 (70 mL improvement, p=0.1607) was not statistically significant. The company plans to engage the FDA on a Phase 3 program, and no timing was given.
Treatment failure through Week 4 was reduced 81% versus placebo (p=0.0122); 2 of 78 rademikibart participants and 11 of 81 placebo participants experienced treatment failure
FEV1 improved 70 mL at Week 4 versus placebo, but the result was not statistically significant (p=0.1607)
Any treatment-emergent adverse event occurred in 11 (14.1%) rademikibart participants versus 21 (25.9%) placebo participants
Connect plans to engage the FDA on a Phase 3 program; the filing gives no timing for that engagement
FactSet reported fourth-quarter fiscal 2026 revenue of $634.7 million, up 6.3% year over year, while GAAP diluted EPS fell 15.4% to $3.41 and adjusted diluted EPS rose 11.6% to $4.52. The company also issued fiscal 2027 guidance calling for revenue of $2,600 million to $2,625 million and GAAP diluted EPS of $17.00 to $17.50, and on September 24, 2026 its board amended the bylaws to let the board delegate powers to committees and update shareholder nomination procedures.
Q4 GAAP operating income fell 11.7% to $156.6 million; GAAP operating margin was 24.7% versus 29.7%, mainly due to restructuring charges and incentive plan costs.
Full-year fiscal 2026 revenue was $2.48 billion, up 6.7%, while GAAP diluted EPS was $14.57, down from $15.55.
Fiscal 2027 guidance: revenue of $2,600 million to $2,625 million, GAAP diluted EPS of $17.00 to $17.50, and adjusted diluted EPS of $19.25 to $19.65.
Q4 share repurchases totaled $138.0 million, and $356.0 million remained available under the program as of August 31, 2026.
Hyperscale Data and its subsidiaries signed an amendment on September 29, 2026 to their existing loan agreement with JGB-affiliated lenders. Affiliate Ault & Company borrowed an additional $21 million and issued notes totaling $22,580,645, and the maturity of all loans under the agreement was extended to December 14, 2027. The added debt is secured by collateral owned by the guarantors, and the proceeds are to fund a loan to Rockwell One Holdings secured by a Georgia manufacturing facility.
Ault & Company, an affiliate of the Company, borrowed an additional $21 million and issued secured notes totaling $22,580,645 to the lenders.
Maturity of all loans under the Loan Agreement extended to December 14, 2027.
Additional loan is secured by collateral from certain Hyperscale guarantors, including mortgages on owned properties; Milton C. Ault, III and Scott Soura also agreed to guarantee repayment of the notes.
Ault & Company intends to lend the proceeds to Rockwell One Holdings, secured by a first-priority leasehold mortgage on a LaGrange, Georgia property.
In a September 28, 2026 press release, Sable Offshore said it plans to accelerate 4 additional Perforation Addition operations on Platform Hondo, bringing completed operations to 9 of 15 production wells before the expected Q4 2026 restart, up from 5 previously expected. The company estimated July and August oil sales at approximately 32 thousand gross barrels per day and expects September at approximately 34 thousand, while noting third-party sales constraints in late August and September.
Platform Hondo reconstruction and internal commissioning are complete; the MMA's final review of the instrumentation, control, and safety submission is expected in October 2026.
Completed Perf Adds before restart are now expected on 9 of 15 wells, versus 5 previously; each is estimated to add about 600 barrels of oil per day at about $800,000 per operation.
July and August oil sales were approximately 32 thousand gross barrels per day; September is expected at approximately 34 thousand.
October nominations to the crude purchaser are expected to average 38 thousand gross barrels per day, with an estimated exit rate of about 45 thousand before Hondo volumes are added.
Talen's board named President Terry Nutt as chief executive effective January 1, 2027, succeeding Mac McFarland, who retires March 1, 2027. The same day, Talen entered $1.5 billion of accelerated share repurchase agreements, funded by selling about $1.5 billion of future PJM capacity revenues, and raised its remaining buyback authorization to $3.0 billion. For shareholders, the buyback reduces the share count, but the company says its adjusted free cash flow forecast for 2H 2026 through 2028 falls from about $4 billion to about $2.8 billion after the capacity sale.
Terry Nutt becomes CEO and joins the board on January 1, 2027; his base salary is set at $1,200,000, with a target bonus of 135% of base and a long-term incentive target of 700% of base.
Mac McFarland serves as Senior Advisor from January 1, 2027 until his retirement on March 1, 2027, and will receive $100,000 for those services.
The ASRs with Goldman Sachs & Co. LLC and Banco Santander cost $1.5 billion, with about 4.0 million shares initially received; the company expects them to be completed by the end of the first quarter of 2027 and says they would repurchase m
The capacity monetization covers PJM 2027/2028 and 2028/2029 delivery years, with Citi, at SOFR plus 200 basis points; the company targets net leverage of 3.5x by the second half of 2027.
Concentrix reported fiscal third-quarter 2026 revenue of $2,453.7 million, down 1.2% from a year earlier, and a GAAP net loss of $988.1 million, or $(16.24) per diluted share, driven by a non-cash $1,050.0 million goodwill impairment. Excluding non-GAAP items, diluted EPS rose 5.0% to $2.92, and the company raised its quarterly dividend to $0.37 per share. The company guided fourth-quarter non-GAAP diluted EPS to $2.86 to $2.98 and full-year 2026 non-GAAP diluted EPS to $10.97 to $11.09.
Revenue was $2,453.7 million, down 1.2% as reported and down 0.5% in constant currency
GAAP operating loss of $(910.3) million and net loss of $(988.1) million include a $1,050.0 million goodwill impairment
Non-GAAP operating income rose 1.3% to $309.0 million and non-GAAP net income rose 1.8% to $186.5 million
Quarterly dividend raised to $0.37 from $0.36, payable November 3, 2026; no shares repurchased in the quarter, with $396.6 million authorization remaining
Fox Factory Holding Corp. completed the sale of Wheelhouse Holdings, parent of baseball bat maker Marucci Sports, to Squared Up Holdings, an investor group led by Marucci senior management, on September 25, 2026. The Company received $200 million in cash, which it used to reduce borrowings under its credit facility, plus a $25 million subordinated note due December 31, 2026. The unaudited pro forma financial information filed with the 8-K shows a $120.1 million loss on the disposal, which weighs on shareholders even as it reduces debt.
Enterprise value of $225 million, paid as $200 million in cash and a $25 million subordinated convertible note
Note matures December 31, 2026; if unpaid, principal increases by $2.5 million and interest rises to 10% per year
Pro forma loss on disposal of $120.1 million and approximately $7.5 million in transaction costs
Pro forma six-month net sales fell to $647.6 million from $726.8 million historical
Workday reiterated its fiscal 2027 third-quarter and full-year guidance from August 27, 2026, except for GAAP operating margin, which it now expects to be roughly 20 to 21 percentage points below non-GAAP margin in the third quarter and about 19 points below for the full year. The company is reducing about 2.5% of its workforce, mainly in Product and Technology, and reducing leased office space, with charges of $65 million to $80 million that shareholders will see in GAAP results.
Reorganizations announced September 29, 2026 include a reduction of about 2.5% of current workforce, mainly in Product and Technology.
Charges of $65 million to $80 million: about $55 million to $70 million in fiscal Q3 and $10 million in fiscal Q4 2027.
Charges include $40 million to $55 million in cash severance and benefit costs, about $10 million in stock-based compensation, and about $15 million in office space impairment.
Employee actions are expected to be substantially complete by Q1 fiscal 2028; office actions by Q4 fiscal 2027.
uniQure presented additional data from its ongoing Phase I/II studies of AMT-130 for Huntington's disease, comparing treated patients with updated external controls. The 36-month analysis of all 15 high-dose patients showed 80% slowing on cUHDRS (nominal p=0.005) and 67% on TFC (nominal p=0.011), and the company says the BLA submission was based on 36-month data. The 48-month primary cUHDRS result showed 44% slowing but did not reach statistical significance (p=0.144), and the company notes that missing data and survivor bias in the updated control may understate the treatment effect.
36-month analysis of 15 high-dose patients: 80% slowing of cUHDRS decline (nominal p=0.005) and 67% slowing of TFC decline (nominal p=0.011)
48-month analysis of 12 high-dose patients: 44% slowing on cUHDRS (p=0.144, not significant) and 61% slowing on TFC (nominal p=0.008)
Data missingness in the updated Enroll-HD B control reached 53% at Month 48; data cutoff was June 30, 2026
Company says the BLA was submitted on 36-month data, which the FDA said at a June 2026 Type B meeting would be acceptable under the accelerated approval pathway
Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate (OLC) on September 29, 2026, with chemistry and manufacturing data from a new third-party drug product vendor. The company expects FDA acceptance within 30 days and a new PDUFA date six months from resubmission, following a June 2026 Complete Response Letter. The company also appointed Meredith S. Manning as an independent director effective October 1, 2026.
NDA resubmitted September 29, 2026, including CMC data from a new third-party drug product manufacturing vendor and 12 months of OLC drug product stability data.
Company anticipates FDA acceptance within 30 days; new PDUFA date expected six months from resubmission.
June 2026 CRL cited the same third-party manufacturing deficiencies as the June 2025 CRL; the original vendor's FDA inspection had not occurred as of September 29, 2026.
Meredith S. Manning appointed independent director effective October 1, 2026; cash, equivalents and marketable securities were $61.4 million as of June 30, 2026.
BeyondSpring agreed to sell its Chinese holding subsidiary, BeyondSpring Ltd., to Biolin Investment Limited. In exchange, Biolin's non-cash consideration is to fund the China portion of the Phase 3 DUBLIN-4 trial, and no cash is payable at closing. The company also set up an at-the-market program to sell up to 9,200,000 ordinary shares, which could dilute existing shareholders, and announced FDA Fast Track designation for Plinabulin.
Sale of BeyondSpring Ltd. to Biolin under a Share Purchase and Collaboration Agreement dated September 28, 2026; no cash paid to the company at closing
If Bulin misses the Target Enrollment within three years after closing, the investor must return part or all of the equity interests, with 100% returned if the shortfall is 90% or greater
ATM program with Citizens JMP Securities for up to 9,200,000 ordinary shares, with commission of up to 3.0% of gross proceeds
FDA granted Fast Track designation to Plinabulin and docetaxel for post-ICI non-squamous NSCLC; DUBLIN-4 plans approximately 442 patients with an interim analysis at 221 PFS events
Aldeyra Therapeutics said it intends to submit a Formal Dispute Resolution Request to the FDA, appealing the March 16, 2026 Complete Response Letter that denied approval of reproxalap for dry eye disease. The company also extended its projected operational cash runway into 2029, based on $45.1 million in cash and cash equivalents as of June 30, 2026. The appeal's outcome and timing remain uncertain, and the filing states that the FDRR submission and meeting with the Office of New Drugs are expected in the fourth quarter of 2026.
Intends to submit an FDRR to the FDA's Office of New Drugs, appealing the March 16, 2026 Complete Response Letter for reproxalap
FDRR submission and a meeting with the Office of New Drugs are expected in the fourth quarter of 2026
Cash and cash equivalents were $45.1 million as of June 30, 2026; operational cash runway extended into 2029
Stewards completed its acquisition of Envy Pompano Beach, a 214-unit apartment and mixed-use property in Florida, on September 23, 2026, with a contractual price of $90.0 million paid partly in 14,263,025 newly issued common shares. The company must make $3.0 million monthly cash payments to sellers from October 2026 through April 2027, while 7,000,000 escrowed shares are cancelled over that period, and it took on a $47.7 million mortgage loan, which adds share dilution and cash obligations for shareholders.
Closed September 23, 2026; contractual price of $90.0 million, including 14,263,025 shares at a $3.00 contractual value per share and $44,557,435.93 of refinanced property debt
7,000,000 shares placed in escrow; $3.0 million cash payments due monthly from October 5, 2026 through April 5, 2027, with 1,000,000 escrowed shares cancelled per payment
$47.7 million LoanCore mortgage loan at one-month Term SOFR (3.35% floor) plus 3.60%, interest-only, maturing October 9, 2028
If shares are delisted from Nasdaq and not relisted within 120 days, the company must pay sellers $5.5 million per payment, subject to a $33.0 million aggregate cap
Summit Therapeutics agreed on September 28, 2026 to sell 108,955.3686 shares of Class A Convertible Preferred Stock to AstraZeneca Holdings B.V. for $2.0 billion in gross proceeds, and also signed a separate clinical trial collaboration with AstraZeneca on sonesitatug vedotin combined with ivonescimab. Shareholders would face dilution once the preferred converts into common stock, which is subject to conditions and a registration statement, and the company must redeem the preferred for cash if a required share authorization is not effective within 18 months.
Purchase price of $18,356.14 per preferred share, based on a common stock price of $18.3561; each preferred share converts into 1,000 common shares
Closing is expected within five business days of the Purchase Agreement, subject to customary conditions
Conversion is barred until the later of any Hart-Scott-Rodino waiting period expiration and effectiveness of the authorized share increase charter amendment
Company must file a resale registration statement within 60 days after closing; cash redemption required if the share increase is not effective within 18 months
On September 28, 2026, AAR agreed to acquire a 65% controlling interest in MRO Holdings, an aircraft maintenance provider, for an estimated cash price of $1,819,174,310 plus Series A preferred stock with an agreed value of $780,825,690, subject to adjustments and closing conditions including regulatory approvals. The deal is expected to close in AAR's fiscal third quarter ending February 2027 and is to be funded partly by about $2.1 billion of new debt, which AAR expects to take net leverage to about 3.6x at closing. The filing also notes that a private investment in public equity offering may dilute existing stockholders, and the company's fiscal 2026 adjusted EBITDA was $401.1 million, up from $324.2 million.
Estimated cash purchase price of $1,819,174,310 and Series A preferred stock with an agreed value of $780,825,690, plus a $22,500,000 escrow deposit
Implied enterprise value of $4.0 billion; AAR expects about $2.1 billion of new debt financing and net leverage of about 3.6x at closing
Expected close in fiscal third quarter ending February 2027, subject to regulatory approvals; termination fee of $100,000,000 ($150,000,000 if the outside date is extended) applies if competition approvals fail
Press release shows fiscal 2026 net income of $187.7 million versus $12.5 million in fiscal 2025, and adjusted EBITDA of $401.1 million versus $324.2 million
Sabre Financial Borrower, a Sabre subsidiary, issued $1.35 billion of 9.875% senior secured notes maturing October 15, 2032, and used the proceeds to refinance part of Sabre GLBL's debt and repurchase portions of its 10.750% and 11.125% notes due 2029 through tender offers. The filing also reports early tender results showing more than 90% of a separate 11.125% note series tendered, which the company plans to redeem, so the refinancing reshapes Sabre's debt structure and secured creditor position.
SPV Notes: $1.35 billion principal, 9.875% annual interest, payable April 15 and October 15, maturing October 15, 2032
Sabre GLBL accepted about $251.9 million of 10.750% 2029 notes at $992.50 per $1,000 principal, with proration of about 84.0%
Early tender results: $930.7 million, or 93.07%, of the 11.125% 2029 notes tendered by September 25, 2026; redemption expected October 13, 2026
Settlement of the tender offers is expected September 28, 2026
Exascale Labs reported fiscal 2026 revenue of $14.8 million, up 111% from $7.0 million, but its net loss widened to $12.2 million from $7.7 million. The loss increase reflects higher operating expenses and a $7.4 million non-cash fair value change on simple agreements for future equity (SAFEs), which converted into Class A common stock when the Nasdaq business combination closed on August 27, 2026, eliminating a $29.1 million liability.
Revenue was $14.8 million versus $7.0 million; revenue from the intelligent computing power service rose 124.0%.
Net loss was $12.2 million versus $7.7 million, including a $7.4 million change in fair value of SAFEs.
Operating expenses rose to $7.2 million from $4.2 million; gross margin was 16.3% versus 15.8%.
Business combination closed August 27, 2026, with approximately $11.8 million in net cash proceeds; shares began trading on Nasdaq as XLAB on August 28, 2026.
Core Molding Technologies furnished slides from its September 28, 2026 investor day under Item 7.01, with the presentation attached as Exhibit 99.1 and posted on its website. The slides show trailing-twelve-month revenue fell from $377 million in 2022 to $254 million through the second quarter of 2026, while the company says its adjusted EBITDA margin improved from 8.7% in 2025 to 11.2%, which it presents as the result of its operating turnaround.
Trailing-twelve-month revenue of $254 million through Q2 2026, versus $274 million in 2025 and $377 million in 2022 per the slides
Adjusted EBITDA margin improved from 8.7% in 2025 to 11.2% per the slides; adjusted EBITDA is a non-GAAP measure
Slides cite $89 million of incremental annual revenue from new wins over 18 months and $210 million of annual revenue in active quotes
CEO Eric Palomaki and CFO Alex Panda are among presenters; the company says it aims to reach $500 million in revenue through economies of scale
Greenpro Capital Corp. completed the sale of six subsidiaries, collectively the F&A Entities, to Ms. Chen Yanhong on September 28, 2026, for cash consideration of HK$3,500,000, or about US$446,486. The filing says the F&A Entities are reported as discontinued operations and that the company estimates a $130,679 loss on the sale, so shareholders will see a smaller continuing business with a one-time loss.
Sale completed September 28, 2026, for HK$3,500,000 (about US$446,486) in cash to Ms. Chen Yanhong.
The buyer is a director of four of the sold entities and holds 14 shares of Greenpro common stock.
The company estimates a $130,679 loss on the sale and a $5,303,075 reduction in additional paid-in capital from waived intercompany balances.
Pro forma six-month 2026 revenue from continuing operations was $431,828, versus $707,553 historically; the F&A Entities principally provided corporate advisory and company-secretarial services.
MongoDB said CEO Chirantan Desai is stepping down, effective September 28, 2026, and that the board appointed former CEO Dev Ittycheria as interim President and CEO. The company said it has started a search for a permanent CEO and reaffirmed its fiscal 2027 and third-quarter guidance, which matters to shareholders because it changes the company's leadership while its outlook stays unchanged.
Chirantan Desai's resignation as President and CEO is effective September 28, 2026; the filing says it is not due to any disagreement with the company.
Dev Ittycheria, CEO from 2014 to 2025 and a board member since 2014, was appointed interim President and CEO effective September 28, 2026.
The board has begun a search for a permanent CEO and retained an executive search firm.
MongoDB reaffirmed its guidance for Q3 and full-year fiscal 2027 provided on September 1, 2026; an Investor Day is set for September 29, 2026, from 11:00 a.m. to 3:15 p.m. ET.
TransCode Therapeutics reported updated Phase 1a clinical data for TTX-MC138 in patients with advanced solid tumors, using a September 1, 2026 data cutoff. Ten of 14 efficacy-evaluable patients achieved stable disease, and no dose-limiting toxicities were reported, but the sample is small and disease control was lower at Cycle 6 (35.7%) than at Cycle 3 (57.1%). The filing contains no financial results, so the update bears on the drug's clinical prospects rather than on current financials.
10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease as best overall response at the September 1, 2026 data cutoff.
Disease control rate was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1.
No dose-limiting toxicities were reported, including at the highest evaluated dose of 4.8 mg/kg, with 98 doses administered.
Post-hoc analysis found 6 of 15 evaluable patients (40%) with a growth modulation index above 1.3; the company said biomarker findings are hypothesis-generating.
After the market close on September 25, 2026, a jury awarded $5.7 billion in damages to the plaintiff in Taction Technology, Inc. v. Apple Inc., a case in which Burford has a financial entitlement. Burford says that if the verdict were paid as is, its entitlement would be $1.4 billion, split roughly equally between its balance sheet and its investment funds, but the amount is likely to change in post-trial and appellate proceedings. For shareholders, the verdict is not a final judgment or cash received, and Burford warns it could recover substantially less or incur a total loss.
Jury verdict of $5.7 billion in damages, announced in a release dated September 28, 2026, after the market close on Friday, September 25, 2026
If paid as is, Burford's entitlement would be $1.4 billion, split roughly equally between its balance sheet and its investment funds
Apple has filed a motion for judgment as a matter of law, and the Federal Circuit will scrutinize large verdicts on appeal
Burford states that it could recover substantially less than the verdict amount or, in certain circumstances, incur a total loss
On September 24, 2026, Celularity closed the initial phase of a financing agreement signed September 23 for up to $25.0 million of senior secured convertible notes, raising $11.01 million in gross proceeds with warrants for about 4,037,000 shares. The filing also shows a September 18 settlement with Helena in which 2,000,000 additional shares were issued, and the notes and warrants could add substantial share dilution for existing holders.
Initial closing on September 24, 2026: $11.01 million in notes, convertible at $1.50 per share into about 7,340,000 shares
Warrants for about 4,037,000 shares, exercisable at $1.50 per share for five years
Notes bear 10% interest, mature 24 months after issue, and are secured by substantially all company and subsidiary assets
Helena settlement dated September 18, 2026: 700,000 shares issued on conversion of $1.197 million at $1.71 per share, plus 2,000,000 additional shares
The Marygold Companies (TMC), which indirectly owns United States Commodity Funds LLC, the general partner of United States Gasoline Fund (UGA), agreed on September 25, 2026 to be acquired by private equity firm Madison Dearborn Partners in an all-cash transaction. The deal would take TMC private and delist its stock from the New York Stock Exchange, and the filing says the deal may not be completed.
Agreement announced September 25, 2026 with Madison Dearborn Partners, a Chicago-based private equity firm
Transaction is expected to close in the first half of 2027 or earlier, subject to conditions
Closing requires approval of TMC stockholders, regulatory approvals and certain change-of-control approvals
TMC common stock will no longer be listed on the New York Stock Exchange after closing; the filing says there is no guarantee the deal will close
On September 21, 2026, MARA's subsidiary Volt Texas LLC amended its July 2, 2026 agreement to acquire MAT 1177 LLC, which holds land rights and a site for a planned data center project in Texas. The amendment requires a $100.0 million security deposit to the Electric Utility Company, which Buyer may withdraw at its discretion subject to a sale process, and restructures milestone payments while keeping the aggregate purchase price at $600 million if all milestones are achieved. The filing also replaces the provision allowing the membership interests to be returned to the seller with a process to market the project for sale to a third party, with the seller holding a right of first offer.
Amendment dated September 21, 2026 to the Membership Interest Purchase Agreement originally dated July 2, 2026
Buyer posted a $100.0 million security deposit with the Electric Utility Company for power capacity for the Site
Aggregate purchase price remains $600 million if all milestones are achieved
Reconveyance provisions replaced by a process to market the project for sale, with a seller right of first offer in certain trigger events
BCB Bancorp, Inc. said its bank agreed between September 21 and September 24, 2026 to sell problem loan portfolios with an aggregate unpaid principal balance of about $205.3 million as of June 30, 2026, with six purchasers. The company estimates a pre-tax loss of $43.3 million from the sales, to be recorded in the third quarter of 2026, and says the sales reduce balance sheet risk.
Six definitive agreements with six different purchasers; aggregate unpaid principal balance of about $205.3 million as of June 30, 2026
Portfolios include $180.7 million of commercial and multifamily real estate loans, $14.8 million of C&I loans, and $9.8 million of construction loans
Estimated pre-tax loss of $43.3 million, to be recorded in the third quarter of 2026
Five of the six sale transactions have closed; the last is expected to close before the end of the third quarter of 2026
Fathom Holdings and Neighborhood Intelligence (NXH) said on September 24, 2026, that they agreed to explore an alternative transaction in place of the merger agreement signed June 16, 2026. Under the proposal, NXH would contribute digital assets, led by its stake in tZERO, in exchange for newly issued Fathom shares, and would keep a controlling interest in Fathom. For shareholders, the original share exchange would be replaced by a deal that could change Fathom's ownership and control, and the companies say there is no assurance it will be completed.
The Original Merger Agreement, dated June 16, 2026, would be terminated once definitive documents are signed.
NXH's digital assets would be ascribed no less than $130 million in value, driven mainly by its approximately 38.8% direct and indirect stake in tZERO, subject to Fathom's validation.
NXH expects to keep a controlling interest in Fathom, and the final share count will be set in definitive agreements.
The deal remains subject to definitive agreements, Fathom and NXH board and Fathom stockholder approvals, an independent fairness opinion, and regulatory approvals.
At its September 24, 2026 annual meeting, AMC stockholders did not approve three charter amendments, including declassifying the board, because each needed a majority of outstanding shares and fell short. Stockholders also rejected the non-binding say-on-pay vote, while approving an increase in the 2024 equity plan from 25,000,000 to 50,000,000 shares.
Declassification charter amendment (Proposal 1) received 361,713,796 For votes, 40.5% of shares outstanding, short of the majority required
Non-binding advisory vote on executive compensation failed, with 54.7% of votes cast against
Stockholders approved raising the 2024 equity incentive plan share limit from 25,000,000 to 50,000,000 shares
Denise M. Clark, Sonia Jain and Keri S. Putnam were elected as Class III directors with terms expiring at the 2029 annual meeting
Patriot National Bancorp agreed on September 23, 2026 to sell 4,782,608 shares of voting common stock at $1.15 per share to accredited investors in a registered direct offering, with no underwriter or placement agent. The company expects about $5.5 million in gross proceeds, less estimated offering expenses of $350,000, and plans to invest the capital in its subsidiary Patriot Bank NA and for general corporate purposes. The sale adds shares outstanding and includes five-year warrants for 956,522 non-voting common shares exercisable at $1.25, which may dilute existing shareholders.
Shares sold: 4,782,608 voting common shares at $1.15 each, dated September 23, 2026
Expected gross proceeds: approximately $5.5 million; estimated offering expenses: $350,000
Warrants: 956,522 five-year warrants, one for every five shares purchased, exercisable no earlier than six months after closing at $1.25 per share
Proceeds to fund Patriot Bank NA and general corporate purposes; offering made under an S-3 shelf effective May 22, 2025
Akamai entered two project plans under its existing Anthropic master services agreement, under which Anthropic has committed to pay about $11.6 billion over initial seven-year terms, subject to termination rights and delivery requirements. Akamai also issued Anthropic a warrant for Series B preferred stock that would convert into up to about 7.7 million common shares, roughly 5% of shares outstanding, with about 2% expected to vest on the initial commitment. Akamai said the deal is not expected to affect its 2026 revenue guidance but will raise 2026 capital expenditures by about $1.7 billion, and the filing's total capital expenditure estimate for the commitment is about $5.5 billion.
Anthropic has committed to pay about $11.6 billion in aggregate under Project Plans 2 and 3, each with an initial seven-year term, dated September 18, 2026
Warrant for 387,051 shares of Series B Non-Voting Convertible Preferred Stock, each convertible into 20 common shares, for up to 7,741,020 common shares on an as-converted basis
Total capital expenditures tied to the $11.6 billion commitment are estimated at about $5.5 billion, with about $1.7 billion more in 2026 capital expenditures for supply chain components including memory
Akamai anticipates no impact to its 2026 revenue guidance
AtlasClear reported fiscal 2026 results for the year ended June 30, 2026, with total revenue up 85% to $20.1 million. Net income was $2.0 million, or $0.02 per share, down from $5.8 million, or $0.96 per share, in fiscal 2025, and the loss from operations widened to $9.8 million, with the net result supported by non-cash fair-value gains.
Total revenue rose to $20.1 million from $10.9 million, with stock locate revenue at $6.8 million versus $0.3 million
Loss from operations was $9.8 million, compared with $4.9 million in fiscal 2025
Net income was $2.0 million, including an $11.1 million non-cash gain on the earnout liability; fiscal 2025 net income was $5.8 million
Cash and cash equivalents totaled $15.4 million at June 30, 2026, versus $7.5 million a year earlier
TTM Technologies completed a $500 million private offering of 6.750% senior notes due 2034 on September 24, 2026. Proceeds, along with $300 million and $800 million of incremental term loans, are intended to fund the pending acquisition of EDS Intermediate Holding, LLC and related costs, with some funds possibly used to reduce revolver borrowings for the Swiss Technology Group AG acquisition. The filing adds substantial new debt and restricts dividends and other payments to shareholders, and the notes become subject to mandatory redemption if the EDS acquisition does not close by the November 15, 2026 outside date, subject to extension.
$500 million of 6.750% senior notes due October 1, 2034, priced at par and issued September 24, 2026
Planned financing also includes a $300 million incremental term loan A and an $800 million incremental term loan B
Notes must be redeemed at 100% of principal plus interest if the EDS acquisition does not close by November 15, 2026 (extendable to May 15, 2027 in certain cases)
Indenture limits dividends, share repurchases and certain other payments to shareholders
Trio-Tech International reported fiscal 2026 revenue of $62.6 million, up 72% from $36.5 million, with a fiscal 2026 net loss attributable to common shareholders of $34,000 versus $41,000 in fiscal 2025. Fourth-quarter revenue rose about 40% to $14.9 million, but the company posted a net loss of $199,000 after net income of $183,000 a year earlier, and gross margin fell to 19% from 25%.
Fiscal 2026 revenue was $62.6 million, with Semiconductor Back-end Solutions revenue up 99% to $49.0 million.
Fourth-quarter operating loss was $266,000, compared with operating income of $467,000 a year earlier.
Total backlog was $24.2 million at June 30, 2026, compared with $11.0 million a year earlier.
Fiscal 2027 first-quarter bookings to date in Industrial Electronics total about $4.6 million, according to the company.
RAVE Restaurant Group reported fourth-quarter and fiscal 2026 results for the year ended June 28, 2026. Fourth-quarter revenue rose to $3.4 million while net income fell 6.2% to $0.8 million, but full-year net income rose to $2.9 million from $2.7 million. The filing also discloses that CEO Brandon Solano sent a complaint on August 31, 2026, alleging workplace harassment and discrimination by the Board, and that the company engaged Hagan Law Group on September 1, 2026 to investigate.
Q4 fiscal 2026 total revenue increased $0.3 million to $3.4 million, up 8.8% year over year; net income was $0.8 million, down 6.2%
Fiscal 2026 net income was $2.9 million ($0.20 per diluted share) versus $2.7 million ($0.19) in fiscal 2025; revenue was $12.9 million
Pie Five domestic comparable store sales fell 17.3% in Q4 and 9.9% for the year; Pizza Inn comparable sales rose 2.4% for the year
On August 31, 2026, CEO Brandon Solano sent a complaint to the Audit Committee Chairman; Hagan Law Group was engaged September 1, 2026 to investigate
New Era Energy & Digital, Inc. entered into a sales agreement allowing it to sell up to $100 million of common stock through several agents over time, with no obligation to sell any shares. The company also disclosed that a Texas order halting data center permits could delay permits needed for its TCDC and other projects, and that it is negotiating with potential tenants, including an anchor tenant for its flagship project.
Up to $100 million of common stock may be sold through six agents under the Sales Agreement dated September 24, 2026.
Agents receive a commission of up to 3.5% of gross proceeds from each sale, plus reimbursement of legal fees.
Proceeds are intended for general corporate purposes, which may include capital expenditures, working capital and debt repayment.
On September 21, 2026, Texas Governor Greg Abbott directed the Texas Commission on Environmental Quality to halt data center permits until an ERCOT audit is complete.
On September 23, 2026, HCW Biologics agreed to sell 903,614 units to an existing institutional investor for approximately $1.5 million in gross proceeds before offering expenses. Each unit pairs a pre-funded warrant with the right to receive a common warrant at $1.66 per share, which is issuable only after stockholder approval that the company is obligated to seek. The company plans to use the proceeds for working capital, clinical development and general corporate purposes, and it agreed to register the resale of the shares underlying the warrants, which could add shares to the market.
903,614 units sold at $1.6599 per unit; pre-funded warrants have a $0.0001 exercise price
Common warrants for up to 903,614 shares, exercisable at $1.66 per share for 5.5 years after issuance, subject to stockholder approval under Nasdaq Rule 5635(d)
Maxim Group LLC is the sole placement agent
Company must file a resale registration statement within 15 trading days after closing and use commercially reasonable efforts to have it declared effective within 60 days
aTyr Pharma said it has reached alignment with the FDA on the protocol for a planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The company expects to start study-related activities in the fourth quarter of 2026 and to focus on regulatory submissions in the U.S. and Europe, but the filing states that future development will require additional capital through equity or debt offerings, grant funding, collaborations, partnerships or licensing.
Planned 54-week, randomized, double-blind, placebo-controlled study of up to approximately 372 patients
Efzofitimod 5.0 mg/kg or placebo given intravenously once every 3 weeks for a total of 17 doses
Primary endpoint is change from baseline in forced vital capacity at week 48; key secondary endpoint is King's Sarcoidosis Questionnaire-Lung score
Study-related activities expected to begin in the fourth quarter of 2026
Decoy Therapeutics reduced the exercise price of its Series B milestone warrants from $5.91 to $3.25 per share, and the holder exercised 1,184,434 of them in full, bringing approximately $3.85 million in gross proceeds before placement agent fees and expenses; the transaction closed September 23, 2026. In exchange, the company issued new unregistered warrants for up to 2,368,868 shares at $3.25 per share, exercisable immediately and expiring five years after issuance, which could add meaningful share count dilution for existing holders.
1,184,434 Series B Milestone Warrants exercised in full on September 22, 2026 at a reduced price of $3.25, down from $5.91 per share.
Gross proceeds of approximately $3.85 million, before placement agent fees and other expenses, to be used for working capital and general corporate purposes.
New unregistered warrants for up to 2,368,868 shares at $3.25 per share, exercisable immediately, expiring five years from issuance.
The company agreed to file a resale registration statement within 15 calendar days of the September 22, 2026 inducement letter.
Sun Communities closed the sale of its UK business, Park Holidays, to Panther Bidco Limited, an affiliate of Aermont Capital, on September 22, 2026. The company received net cash proceeds of approximately $1.03 billion and says it expects to use them primarily for share repurchases, debt repayment and general corporate purposes. The company previously recorded a $1.1 billion valuation allowance charge on the UK business in the second quarter of 2026, and it will update its full-year 2026 outlook on its third quarter earnings call.
Closed on September 22, 2026; buyer Panther Bidco Limited is an affiliate of Aermont Capital
Net cash proceeds of approximately $1.03 billion after closing and transaction costs
Valuation allowance charge of $1.1 billion recorded in the three months ended June 30, 2026
Year-to-date through September 21, 2026, the company repurchased about 3.5 million shares for about $425 million
ONE Nuclear Energy LLC and Hennessy Capital Investment Corp. VII closed their business combination on September 23, 2026, and the combined company was renamed ONE Nuclear Energy Inc. Its common stock is expected to begin trading on Nasdaq under the ticker ONEN on or about September 24, 2026. Holders of 13,809,029 SPAC shares redeemed them for about $146.5 million, leaving about $2.2 million in the trust account before expenses, which the company says is intended to provide capital access for its 5 GW Louisiana Portfolio.
Holders of 13,809,029 Class A ordinary shares redeemed them at about $10.61 per share, for about $146.5 million in total
About $2.2 million remained in the Hennessy VII trust account after redemptions and forward purchase prepayments, before paying expenses
Nasdaq trading under ONEN expected on or about September 24, 2026
Portfolio includes Project Amberjack (up to 1 GW SMR), Project Cayman (2.88 GW gas plant) and Project Barracuda (1.2 GW gas plant)
Cayson Acquisition Corp shareholders approved at an extraordinary general meeting on September 23, 2026 an amendment letting the board extend the company's deadline to complete a business combination monthly, up to 12 months, to September 23, 2027. Holders of 1,428,025 public shares redeemed them for a pro rata share of the trust account, and the company's CEO loaned $60,000 to fund the trust deposit for the extension, which the filing says is repayable only upon a business combination.
Extension proposal approved with 2,858,762 votes for and 1,357,803 against
Holders of 1,428,025 public shares exercised redemption rights
CEO Yawei Cao loaned $60,000 to the company, deposited into the trust account, with no interest
Company states it continues to seek an initial business combination
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.